HUAWEI
28.2.2022 16:39:06 CET | Business Wire | Press release
During the Huawei Day 0 Forum at MWC Barcelona 2022, Huawei released a series of new IT products and solutions as part of a new "intelligent IT foundation" for operators. David Wang, Executive Director of the Board and Chairman of the ICT Infrastructure Managing Board at Huawei, explained in his keynote speech titled "+IT, New Growth" that this reliable and efficient IT foundation will help operators go intelligent, increase revenue, reduce costs, boost efficiency, and ultimately achieve new growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220228005736/en/
With the rapid development of emerging technologies like 5G, IoT, cloud computing, and intelligence, operators have put their own digital transformations at the top of their agendas so that they can later help other B2B industries to go digital. This kind of transformation however requires IT infrastructure upgrades, multi-cloud collaboration, and quick market wins to generate more momentum.
Wang explained that Huawei's intelligent IT foundation is specifically designed to help operators meet these new requirements. This foundation includes a fully-collaborative distributed cloud and an all-scenario data pool.
At the same event, Huawei also launched the industry's first ever distributed, cloud-native solution. This fully-collaborative cloud helps operators to achieve ICT orchestration, cloud-network synergy, and cloud-edge synergy. The architecture supports both data and media platforms as a service for operators and application platform as a service (aPaaS) for industry customers. This delivers guaranteed experiences for app users unlimited by geography, multi-cloud collaboration, and data traffic. The company currently says that one day, it hopes to offer everything as a service.
Huawei also announced a new series of data infrastructure products as part of its OneStorage strategy to support continual storage evolution. As data types continue to diversify, applications have become more affordable and data protection is more important than ever. Huawei's OneStorage solution gives operators the efficiency they need to meet these requirements through on-demand resource provisioning, intelligent data management, and multi-cloud convergence. It is currently Huawei's best offering for operators who want to keep their data infrastructure up-to-date and explore new businesses.
By the end of 2021, HUAWEI CLOUD and its partners had built 61 availability zones in 27 areas to serve more than 170 countries and regions. It has also started working with more than 120 operators in the cloud service market to help enterprise customers go digital. It currently offers more than 50 scenario-specific cloud services for nine vertical markets, such as manufacturing, retail, and healthcare, to go digital. These intelligent and efficient data storage services offerings are currently used by 300 operators worldwide and the OceanStor Dorado solution has been named a Leader in Gartner's Magic Quadrant for six years in a row.
Reliable, efficient, and intelligent IT infrastructure is critical for operators to go digital. Huawei wants to continue working with operators to roll out IT infrastructure, help industry go digital, and achieve new growth together.
MWC22 Barcelona will run from February 28 to March 3 in Barcelona, Spain. Huawei will showcase its products and solutions at stand 1H50 in Fira Gran Via Hall 1. Together with global operators, industry professionals, and opinion leaders, we will dive into topics such as industry trends, GUIDE to the Future, and green development to envision the future of digital networks. For more information, please visit: https://carrier.huawei.com/en/events/mwc2022 .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005736/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom